CSF1R通过准RUNX1在免疫性血小板缺血症中调节巨核形成
Haohao Han1, Meng Zhou1, Jiaqian Qi1
1National clinical research center for hematologic diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou.
Haematologica
|December 19, 2025
概括
免疫性血小板缺血 (ITP) 涉及血小板问题和大胆细胞 (MK) 生产受损. 向殖民地刺激因子1受体 (CSF1R) 改善了MK功能,并加速了ITP中的血小板恢复.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 免疫性血小板缺血 (ITP) 是一种自身免疫性疾病,由于血小板的破坏和较差的巨细胞形成,导致出血.
- 在ITP中巨核细胞 (MK) 功能障碍的确切机制尚未完全理解.
研究的目的:
- 为了研究在免疫性血小板缺陷时,巨核细胞功能障碍背后的分子机制.
- 确定ITP的潜在治疗点.
主要方法:
- 来自ITP患者的骨髓细胞的单细胞RNA测序 (scRNA-seq).
- 在临床样本上使用流细胞计验证.
- 在MK分化和抑制CSF1R的体外研究.
- ITP的小鼠模型来评估CSF1R抑制的有效性.
主要成果:
- scRNA-seq显示了来自ITP患者的MKs中的殖民地刺激因子1受体 (CSF1R) 的显着上调.
- 在ITP中,MK分化和成熟受损,缺陷被CSF1R抑制所挽救.
- 在小鼠ITP模型中,CSF1R抑制加速了血小板恢复.
- 升高的CSF1R抑制了关键的巨核形成调节器RUNX1.1.
结论:
- 在ITP的背景下,CSF1R被确定为巨核形成的新型调节剂.
- 抑制CSF1R证明了改善血小板生产和ITP恢复的治疗潜力.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Role of Hematopoietic Growth Factors
3.1K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
3.1K
Differentiation of Common Myeloid Progenitor Cells
3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K


